報價延遲最少15分鐘:2024/12/25 01:53 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.08/0.19
|
|
企業價值
2.19B
|
| 資產負債 |
|
每股賬面淨值
-0.76
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
198.96M
|
|
每股收益
0.64
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/25 01:53 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |